All In Biotech

Drug Trial Radar · NCT05103423

Safety and Efficacy Study of BDB-001 Injection in Patients With Moderate to Severe Hidradenitis Suppurativa (HS)

A Multicenter, Randomized, Double-blind, Placebo Parallel-controlled, Phase I/II Study to Explore Safety and Efficacy of BDB-001 Injection in Subjects With Moderate to Severe Hidradenitis Suppurativa

Last checked: Nov 19, 2026Latest source record: Mar 26, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

50

Actual

Start

Jun 24, 2021

Primary completion

Jul 7, 2023

Study completion Jul 7, 2023

Sponsor

Sponsor type
Industry
First posted
Nov 2, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A study to explore the safety and efficacy of treatment with BDB-001 Injection in adults with moderate to severe hidradenitis suppurativa (HS).

Conditions

  • Hidradenitis Suppurativa

Interventions

  • BDB-001 InjectionDrug

    Multiple IV infusions of BDB-001 Injection diluted in sodium chloride

  • PlaceboDrug

    Multiple IV infusions of Placebo Injection diluted in sodium chloride

  • PlaceboDrug

    Multiple IV infusions of Placebo Injection diluted in sodium chloride

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of participants with treatment-related adverse events as assessed by CTCAE v5.0.Time frame: Week 8
  2. Number of Participants developing anti-BDB-001 antibodies.Time frame: Week 8
  3. Area under the plasma concentration versus time curve (AUC) of BDB-001 Assessment of pharmacokinetic parameters.Time frame: Week 8
  4. Peak Plasma Concentration (Cmax) of BDB-001and time to reach Cmax Assessment of pharmacokinetic parameters.Time frame: Week 8
  5. Minimal Plasma Concentration (Cmin) of BDB-001 Assessment of pharmacokinetic parameters.Time frame: Week 8
  6. Terminal phase half-life Assessment of pharmacokinetic parameters.Time frame: Week 8

Locations

15 sites in 1 country. Site status is shown where the registry gives one.

  • Peking University First Hospital

    Beijing, Beijing Municipality, China

  • Plastic Surgery Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College

    Beijing, Beijing Municipality, China

  • Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College

    Beijing, Beijing Municipality, China

  • The Third Affiliated Hospital of Sun Yat-sen University

    Guangzhou, Guangdong, China

  • Union Hospital Tongji Medical College Huazong University of Science and Technology

    Wuhan, Hubei, China

  • Xiangya Hospital, Central South University

    Changsha, Hunan, China

  • Chinese Academy of Medical Sciences and Peking Union Medical College

    Nanjing, Jiangsu, China

  • The First Hospital of Jilin Universitv

    Changchun, Jilin, China

  • The First Hospital of China Medical University

    Shenyang, Liaoning, China

  • The First Affiliated Hospital of Air Force Medical University

    Xi'an, Shaanxi, China

  • The Second Affiliated Hospital of Xi'an Jiaotong University

    Xi'an, Shaanxi, China

  • Qilu Hospital of Shandong University

    Jinan, Shandong, China

  • Huashan Hospital of Fudan University

    Shanghai, Shanghai Municipality, China

  • Shanghai Skin Disease Hospital

    Shanghai, Shanghai Municipality, China

  • West China Hospital of Sichuan University

    Chengdu, Sichuan, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.